中华皮肤科杂志 ›› 2026, e20260309.doi: 10.35541/cjd.20260309
• 指南与共识 • 上一篇
中国医师协会皮肤科医师分会性传播疾病专业委员会
收稿日期:2026-06-01
修回日期:2026-10-04
发布日期:2026-11-09
通讯作者:
徐金华;陆小年;周平玉;王千秋
E-mail:xjhhsyy@163.com; luxiaonian@fudan.edu.cn; zhoupingyu@medmail.com.cn; doctorwqq@163.com
Committee on Sexually Transmitted Diseases, China Dermatologist Association
Received:2026-06-01
Revised:2026-10-04
Published:2026-11-09
Contact:
Xu Jinhua; Lu Xiaonian; Zhou Pingyu; Wang Qianqiu
E-mail:xjhhsyy@163.com; luxiaonian@fudan.edu.cn; zhoupingyu@medmail.com.cn; doctorwqq@163.com
摘要: 【摘要】 肛门生殖器疣,又称尖锐湿疣,是由人乳头瘤病毒(HPV)感染所致的良性增生性病变,主要累及肛门生殖器区域皮肤与黏膜。该病传播性强,复发率高,显著影响患者生活质量,目前临床尚无根除HPV感染的特效抗病毒治疗。本指南由中国医师协会皮肤科医师分会性传播疾病专业委员会组织我国性传播疾病及相关领域专家联合制订,遵循指南研究与评价工具(AGREE)第2版国际指南开发规范并结合我国流行病学特征,旨在解决诊断挑战、治疗争议、管理难点等核心问题。规范化诊疗与全流程综合管理是本指南的核心:典型皮损可临床诊断,不典型或特殊部位需联合醋酸白试验、皮肤镜、阴道镜、肛门镜、尿道镜、HPV检测及病理检查,宫颈及肛内疣治疗前需排除癌前病变或癌变;应采取个体化、联合治疗策略清除疣体,重视亚临床感染干预以及潜伏感染的定期随访;疣体清除后随访6 ~ 9个月;针对妊娠、儿童、免疫缺陷等特殊人群实施差异化诊疗;推荐符合接种条件人群接种HPV疫苗,并开展性伴筛查和安全性行为教育。本指南为临床提供标准化诊疗路径,以提升临床规范化诊疗水平,完善疾病综合防控体系。
中国医师协会皮肤科医师分会性传播疾病专业委员会. 中国肛门生殖器疣临床管理指南(2026版)[J]. 中华皮肤科杂志, 2026,e20260309. doi:10.35541/cjd.20260309
Committee on Sexually Transmitted Diseases, China Dermatologist Association. 2026 Chinese Guideline for the Clinical Management of Anogenital Warts[J]. Chinese Journal of Dermatology,2026,e20260309. doi:10.35541/cjd.20260309
| [1] | 李明珠, 赵方辉, 尹如铁, 等. 预防性人乳头瘤病毒疫苗中国临床应用指南(2025版)[J]. 中国妇产科临床杂志, 2025,26(2):176⁃187. DOI: 10.13390/j.issn.1672⁃1861.2025.02.022. |
| [2] | Egawa N, Egawa K, Griffin H, et al. Human papillomaviruses: epithelial tropisms, and the development of neoplasia[J]. Viruses, 2015,7(7):3863⁃3890. DOI: 10.3390/v7072802. |
| [3] | Brown DR, Schroeder JM, Bryan JT, et al. Detection of multiple human papillomavirus types in condylomata acuminata lesions from otherwise healthy and immunosuppressed patients[J]. J Clin Microbiol, 1999,37(10):3316⁃3322. DOI: 10.1128/JCM. 37.10.3316⁃3322.1999. |
| [4] | Schabath MB, Villa LL, Lin HY, et al. Racial differences in the incidence and clearance of human papilloma virus (HPV): the HPV in men (HIM) study[J]. Cancer Epidemiol Biomarkers Prev, 2013,22(10):1762⁃1770. DOI: 10.1158/1055⁃9965.EPI⁃13⁃0303. |
| [5] | Doorbar J. The human Papillomavirus twilight zone ⁃ latency, immune control and subclinical infection[J]. Tumour Virus Res, 2023,16:200268. DOI: 10.1016/j.tvr.2023.200268. |
| [6] | Ryser MD, Bravo IG, Campos NG, et al. IPVS Consensus Statement on The Natural History of Cervical Human Papillomavirus Infection[J]. J Infect Dis, 2026,233(4):735⁃744. DOI: 10.1093/infdis/jiaf574. |
| [7] | Patel H, Wagner M, Singhal P, et al. Systematic review of the incidence and prevalence of genital warts[J]. BMC Infect Dis, 2013,13:39. DOI: 10.1186/1471⁃2334⁃13⁃39. |
| [8] | 梁诗晴, 陈泽伟, 岳晓丽, 等. 2018⁃2023年中国尖锐湿疣流行趋势及时空分布特征[J]. 中华流行病学杂志, 2024,45(8):1073⁃1078. DOI: 10.3760/cma.j.cn112338⁃20240308⁃00107. |
| [9] | 中国疾病预防控制中心性病控制中心, 中华医学会皮肤性病学分会, 中国医师协会皮肤科医师分会, 等. 性传播疾病临床诊疗与防治指南(第2版)[M]. 上海: 上海科学技术出版社, 2020. |
| [10] | Natarajan J, Nilavu LK, Chandrasekaran S. Vulvo vaginal warts: how to manage?[J]. J Colposc Low Genit Tract Pathol, 2024,2(3):83⁃86. DOI: 10.4103/JCLGTP.JCLGTP_15_24. |
| [11] | Petca A, Borislavschi A, Zvanca ME, et al. Non⁃sexual HPV transmission and role of vaccination for a better future (review)[J]. Exp Ther Med, 2020,20(6):186. DOI: 10.3892/etm.2020. 9316. |
| [12] | Yamaguchi M, Sekine M, Hanley S, et al. Risk factors for HPV infection and high⁃grade cervical disease in sexually active Japanese women[J]. Sci Rep, 2021,11(1):2898. DOI: 10.1038/s41598⁃021⁃82354⁃6. |
| [13] | 岳晓丽, 龚向东, 李婧, 等. 2008—2016年中国性病监测点尖锐湿疣流行特征分析[J]. 中华皮肤科杂志, 2017,50(5):321⁃325. DOI: 10.3760/cma.j.issn.0412⁃4030.2017.05.003. |
| [14] | Zhu C, Wang Y, Mao W, et al. Prevalence and distribution of HPV types in genital warts in Xi'an, China: a prospective study[J]. BMJ Open, 2019,9(5):e023897. DOI: 10.1136/bmjopen⁃2018⁃023897. |
| [15] | Larsen HK, Thomsen LT, Hædersdal M, et al. Risk of anogenital warts in renal transplant recipients compared with immunocompetent controls: a cross⁃sectional clinical study[J]. Acta Derm Venereol, 2021,101(7):adv00497. DOI: 10.2340/00015555⁃3858. |
| [16] | Tyros G, Mastraftsi S, Gregoriou S, et al. Incidence of anogenital warts: epidemiological risk factors and real⁃life impact of human papillomavirus vaccination[J]. Int J STD AIDS, 2021,32(1):4⁃13. DOI: 10.1177/0956462420958577. |
| [17] | Drolet M, Bénard É, Pérez N, et al. Population⁃level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta⁃analysis[J]. Lancet, 2019,394(10197):497⁃509. DOI: 10.1016/S0140⁃6736(19)30298⁃3. |
| [18] | Nugent D, Apoola A, Coleman H, et al. British association for sexual health and HIV national guideline for the management of anogenital warts in adults (2024)[J]. Int J STD AIDS, 2024,35(7):498⁃509. DOI: 10.1177/09564624241233338. |
| [19] | Sindhuja T, Bhari N, Gupta S. Asian guidelines for condyloma acuminatum[J]. J Infect Chemother, 2022,28(7):845⁃852. DOI: 10.1016/j.jiac.2022.03.004. |
| [20] | Stubenrauch F, Laimins LA. Human papillomavirus life cycle: active and latent phases[J]. Semin Cancer Biol, 1999,9(6):379⁃386. DOI: 10.1006/scbi.1999.0141. |
| [21] | Workowski KA, Bachmann LH, Chan PA, et al. Sexually Transmitted Infections Treatment Guidelines, 2021[J]. MMWR Recomm Rep, 2021,70(4):1⁃187. DOI: 10.15585/mmwr.rr7004a1. |
| [22] | Hu W, Shi Y, Guan MM, et al. An analysis of HPV infection and distribution in cervical and genital samples with condyloma acuminatum: a retrospective study[J]. Int J Dermatol Venereol, 2023,6(1):35⁃39. DOI: 10.1097/JD9.0000000000000200. |
| [23] | Zhu P, Qi RQ, Yang Y, et al. Clinical guideline for the diagnosis and treatment of cutaneous warts (2022)[J]. J Evid Based Med, 2022,15(3):284⁃301. DOI: 10.1111/jebm.12494. |
| [24] | Dong H, Shu D, Campbell TM, et al. Dermatoscopy of genital warts[J]. J Am Acad Dermatol, 2011,64(5):859⁃864. DOI: 10.1016/j.jaad.2010.03.028. |
| [25] | Gilson R, Nugent D, Werner RN, et al. 2019 IUSTI⁃Europe guideline for the management of anogenital warts[J]. J Eur Acad Dermatol Venereol, 2020,34(8):1644⁃1653. DOI: 10.1111/jdv. 16522. |
| [26] | Bornstein J, Bentley J, Bösze P, et al. 2011 colposcopic terminology of the International Federation for Cervical Pathology and Colposcopy[J]. Obstet Gynecol, 2012,120(1):166⁃172. DOI: 10.1097/AOG.0b013e318254f90c. |
| [27] | Perkins RB, Guido RS, Castle PE, et al. 2019 ASCCP risk⁃based management consensus guidelines for abnormal cervical cancer screening tests and cancer precursors[J]. J Low Genit Tract Dis, 2020,24(2):102⁃131. DOI: 10.1097/LGT.0000000000000525. |
| [28] | Li L, Yu S, Wu J, et al. Regulation of target⁃activated CRISPR/Cas12a on surface binding of polymer dots for sensitive electrochemiluminescence DNA analysis[J]. Anal Chem, 2023,95(18):7396⁃7402. DOI: 10.1021/acs.analchem.3c01521. |
| [29] | Ma C, Zou M, Xu N, et al. Portable, and ultrasensitive HR⁃HPV tests based on nucleic acid biosensors[J]. Front Cell Infect Microbiol, 2024,14:1357090. DOI: 10.3389/fcimb.2024.1357090. |
| [30] | Park IU, Introcaso C, Dunne EF. Human papillomavirus and genital warts: a review of the evidence for the 2015 Centers for Disease Control and Prevention Sexually Transmitted Diseases Treatment Guidelines[J]. Clin Infect Dis, 2015,61(Suppl 8):849⁃855. DOI: 10.1093/cid/civ813. |
| [31] | Nicolaidou E, Kanelleas A, Nikolakopoulos S, et al. A short, 8⁃week course of imiquimod 5% cream versus podophyllotoxin in the treatment of anogenital warts: a retrospective comparative cohort study[J]. Indian J Dermatol Venereol Leprol, 2021,87(5):666⁃670. DOI: 10.4103/ijdvl.IJDVL_148_19. |
| [32] | Komericki P, Akkilic⁃Materna M, Strimitzer T, et al. Efficacy and safety of imiquimod versus podophyllotoxin in the treatment of anogenital warts[J]. Sex Transm Dis, 2011,38(3):216⁃218. DOI: 10.1097/OLQ.0b013e3181f68ebb. |
| [33] | Edwards L, Ferenczy A, Eron L, et al. Self⁃administered topical 5% imiquimod cream for external anogenital warts [J]. Arch Dermatol, 1998,134(1):25⁃30. DOI: 10.1001/archderm.134.1.25. |
| [34] | Arican O, Guneri F, Bilgic K, et al. Topical imiquimod 5% cream in external anogenital warts: a randomized, double⁃blind, placebo⁃controlled study[J]. J Dermatol, 2004,31(8):627⁃631. DOI: 10.1111/j.1346⁃8138.2004.tb00568.x. |
| [35] | Garland SM, Waddell R, Mindel A, et al. An open⁃label phaseⅡpilot study investigating the optimal duration of imiquimod 5% cream for the treatment of external genital warts in women[J]. Int J STD AIDS, 2006,17(7):448⁃452. DOI: 10.1258/095646 206777689161. |
| [36] | Kirby P, Dunne A, King DH, et al. Double⁃blind randomized clinical trial of self⁃administered podofilox solution versus vehicle in the treatment of genital warts[J]. Am J Med, 1990,88(5):465⁃469. DOI: 10.1016/0002⁃9343(90)90424⁃c. |
| [37] | Claesson U, Lassus A, Happonen H, et al. Topical treatment of venereal warts: a comparative open study of podophyllotoxin cream versus solution[J]. Int J STD AIDS, 1996,7(6):429⁃434. DOI: 10.1258/0956462961918400. |
| [38] | Beutner KR, Conant MA, Friedman⁃Kien AE, et al. Patient⁃applied podofilox for treatment of genital warts[J]. Lancet, 1989,1(8642):831⁃834. DOI: 10.1016/s0140⁃6736(89)92282⁃4. |
| [39] | Strand A, Brinkeborn RM, Siboulet A. Topical treatment of genital warts in men, an open study of podophyllotoxin cream compared with solution[J]. Genitourin Med, 1995,71(6):387⁃390. DOI: 10.1136/sti.71.6.387. |
| [40] | Lacey CJ, Goodall RL, Tennvall GR, et al. Randomised controlled trial and economic evaluation of podophyllotoxin solution, podophyllotoxin cream, and podophyllin in the treatment of genital warts[J]. Sex Transm Infect, 2003,79(4):270⁃275. DOI: 10.1136/sti.79.4.270. |
| [41] | Beutner KR, Spruance SL, Hougham AJ, et al. Treatment of genital warts with an immune⁃response modifier (imiquimod)[J]. J Am Acad Dermatol, 1998,38(2 Pt 1):230⁃239. DOI: 10.1016/s0190⁃9622(98)70243⁃9. |
| [42] | Beutner KR, Tyring SK, Trofatter KF, et al. Imiquimod, a patient⁃applied immune⁃response modifier for treatment of external genital warts[J]. Antimicrob Agents Chemother, 1998,42(4):789⁃794. DOI: 10.1128/AAC.42.4.789. |
| [43] | Fife KH, Ferenczy A, Douglas JM, et al. Treatment of external genital warts in men using 5% imiquimod cream applied three times a week, once daily, twice daily, or three times a day[J]. Sex Transm Dis, 2001,28(4):226⁃231. DOI: 10.1097/00007435⁃200104000⁃00007. |
| [44] | Schöfer H, Van Ophoven A, Henke U, et al. Randomized, comparative trial on the sustained efficacy of topical imiquimod 5% cream versus conventional ablative methods in external anogenital warts[J]. Eur J Dermatol, 2006,16(6):642⁃648. |
| [45] | Carrasco D, vander Straten M, Tyring SK. Treatment of anogenital warts with imiquimod 5% cream followed by surgical excision of residual lesions[J]. J Am Acad Dermatol, 2002,47(4 Suppl):S212⁃216. DOI: 10.1067/mjd.2002.126579. |
| [46] | Kumar B, Narang T. Local and systemic adverse effects to topical imiquimod due to systemic immune stimulation[J]. Sex Transm Infect, 2011,87(5):432. DOI: 10.1136/sextrans⁃2011⁃050025. |
| [47] | Baker DA, Ferris DG, Martens MG, et al. Imiquimod 3.75% cream applied daily to treat anogenital warts: combined results from women in two randomized, placebo⁃controlled studies[J]. Infect Dis Obstet Gynecol, 2011,2011:806105. DOI: 10.1155/2011/806105. |
| [48] | Tatti S, Swinehart JM, Thielert C, et al. Sinecatechins, a defined green tea extract, in the treatment of external anogenital warts: a randomized controlled trial[J]. Obstet Gynecol, 2008,111(6):1371⁃1379. DOI: 10.1097/AOG.0b013e3181719b60. |
| [49] | Gross G, Meyer KG, Pres H, et al. A randomized, double⁃blind, four⁃arm parallel⁃group, placebo⁃controlled PhaseⅡ/Ⅲ study to investigate the clinical efficacy of two galenic formulations of polyphenon E in the treatment of external genital warts[J]. J Eur Acad Dermatol Venereol, 2007,21(10):1404⁃1412. DOI: 10. 1111/j.1468⁃3083.2007.02441.x. |
| [50] | Stockfleth E, Beti H, Orasan R, et al. Topical polyphenon E in the treatment of external genital and perianal warts: a randomized controlled trial[J]. Br J Dermatol, 2008,158(6):1329⁃1338. DOI: 10.1111/j.1365⁃2133.2008.08520.x. |
| [51] | Puviani M, Galluzzo M, Talamonti M, et al. Efficacy of sinecatechins 10% as proactive sequential therapy of external genital warts after laser CO2 ablative therapy: the PACT study (post⁃ablation immunomodulator treatment of condylomata with sinecatechins): a randomized, masked outcome assessment, multicenter trial[J]. Int J STD AIDS, 2019,30(2):131⁃136. DOI: 10.1177/0956462418797874. |
| [52] | O'Mahony C, Gomberg M, Skerlev M, et al. Position statement for the diagnosis and management of anogenital warts[J]. J Eur Acad Dermatol Venereol, 2019,33(6):1006⁃1019. DOI: 10.1111/jdv.15570. |
| [53] | Sherrard J, Riddell L. Comparison of the effectiveness of commonly used clinic⁃based treatments for external genital warts[J]. Int J STD AIDS, 2007,18(6):365⁃368. DOI: 10.1258/095646207781024711. |
| [54] | Batista CS, Atallah AN, Saconato H, et al. 5⁃FU for genital warts in non⁃immunocompromised individuals[J]. Cochrane Database Syst Rev, 2010,2010(4):CD006562. DOI: 10.1002/14651858.CD006562.pub2. |
| [55] | Jin G, Liu Y, Wang S, et al. Efficacy and safety of Chinese patent medicine paiteling in condyloma acuminatum: a systematic review and meta⁃analysis[J]. J Ethnopharmacol, 2024,318(Pt B):116894. DOI: 10.1016/j.jep.2023.116894. |
| [56] | Westfechtel L, Werner RN, Dressler C, et al. Adjuvant treatment of anogenital warts with systemic interferon: a systematic review and meta⁃analysis[J]. Sex Transm Infect, 2018,94(1):21⁃29. DOI: 10.1136/sextrans⁃2017⁃053150. |
| [57] | Herzum A, Ciccarese G, Occella C, et al. Treatment of pediatric anogenital warts in the era of HPV⁃vaccine: a literature review[J]. J Clin Med, 2023,12(13):4230. DOI: 10.3390/jcm12134230. |
| [58] | Eron LJ, Judson F, Tucker S, et al. Interferon therapy for condylomata acuminata[J]. N Engl J Med, 1986,315(17):1059⁃1064. DOI: 10.1056/NEJM198610233151704. |
| [59] | Friedman⁃Kien A. Management of condylomata acuminata with Alferon N injection, interferon alfa⁃n3 (human leukocyte derived)[J]. Am J Obstet Gynecol, 1995,172(42):1359⁃1368. DOI: 10.1016/0002⁃9378(95)90404⁃2. |
| [60] | Syed TA, Ahmadpour OA. Human leukocyte derived interferon⁃alpha in a hydrophilic gel for the treatment of intravaginal warts in women: a placebo⁃controlled, double⁃blind study[J]. Int J STD AIDS, 1998,9(12):769⁃772. DOI: 10.1258/09564629819 21396. |
| [61] | Yang J, Pu YG, Zeng ZM, et al. Interferon for the treatment of genital warts: a systematic review[J]. BMC Infect Dis, 2009,9:156. DOI: 10.1186/1471⁃2334⁃9⁃156. |
| [62] | Nambudiri VE, Mutyambizi K, Walls AC, et al. Successful treatment of perianal giant condyloma acuminatum in an immunocompromised host with systemic interleukin 2 and topical cidofovir[J]. JAMA Dermatol, 2013,149(9):1068⁃1070. DOI: 10.1001/jamadermatol.2013.5160. |
| [63] | Pontini P, Mastorino L, Gaspari V, et al. A multicentre, randomised clinical trial to compare a topical Nitrizinc® complex solution versus cryotherapy for the treatment of anogenital warts[J]. Dermatol Ther (Heidelb), 2020,10(5):1063⁃1073. DOI: 10.1007/s13555⁃020⁃00430⁃7. |
| [64] | Oren⁃Shabtai M, Snast I, Lapidoth M, et al. Topical and systemic retinoids for the treatment of genital warts: a systematic review and meta⁃analysis[J]. Dermatology, 2021,237(3):389⁃395. DOI: 10.1159/000511398. |
| [65] | Li X, Guan Z, Liu Q, et al. Treatment of condylomata acuminata caused by low⁃risk human papillomavirus with chloroquine phosphate gel[J]. Front Med (Lausanne), 2023,10:1171550. DOI: 10.3389/fmed.2023.1171550. |
| [66] | Gincheva D, Gincheva V, Konova E, et al. Effect of combined therapy polyhexamethylene biguanide and Coriolus MRL on human papilloma virus (HPV) cervical and vulvar⁃related lesions[J]. IJMDAT, 2020,3:e220. DOI: 10.32113/ijmdat_20201_220. |
| [67] | Marelli G, Papaleo E, Origoni M, et al. Polyhexamethylene biguanide for treatment of external genital warts: a prospective, double⁃blind, randomized study[J]. Eur Rev Med Pharmacol Sci, 2005,9(6):369⁃372. |
| [68] | Firooz A, Hosseini H, Izadi Firouzabadi L, et al. The efficacy and safety of other cryotherapy compounds for the treatment of genital warts: a randomized controlled trial[J]. J Dermatolog Treat, 2019,30(2):176⁃178. DOI: 10.1080/09546634.2018.14 80745. |
| [69] | Recanati MA, Kramer KJ, Maggio JJ, et al. Cantharidin is superior to trichloroacetic acid for the treatment of non⁃mucosal genital warts: a pilot randomized controlled trial[J]. Clin Exp Obstet Gynecol, 2018,45(3):383⁃386. DOI: 10.12891/ceog4112. 2018. |
| [70] | Guenthner S, McFalda W, Tate M, et al. PhaseⅡ, double⁃blind, vehicle⁃controlled study to determine the cantharidin dose regimen, efficacy, safety, and tolerability of VP⁃102 in subjects with external genital warts[J]. Am J Clin Dermatol, 2021,22(6):867⁃875. DOI: 10.1007/s40257⁃021⁃00635⁃2. |
| [71] | Bertolotti A, Dupin N, Bouscarat F, et al. Cryotherapy to treat anogenital warts in nonimmunocompromised adults: systematic review and meta⁃analysis[J]. J Am Acad Dermatol, 2017,77(3):518⁃526. DOI: 10.1016/j.jaad.2017.04.012. |
| [72] | Azizjalali M, Ghaffarpour G, Mousavifard B. CO2 laser therapy versus cryotherapy in treatment of genital warts; a randomized controlled trial (RCT)[J]. Iran J Microbiol, 2012,4(4):187⁃190. |
| [73] | Chen K, Chang BZ, Ju M, et al. Comparative study of photodynamic therapy vs CO2 laser vaporization in treatment of condylomata acuminata: a randomized clinical trial[J]. Br J Dermatol, 2007,156(3):516⁃520. DOI: 10.1111/j.1365⁃2133. 2006.07648.x. |
| [74] | Liang J, Lu XN, Tang H, et al. Evaluation of photodynamic therapy using topical aminolevulinic acid hydrochloride in the treatment of condylomata acuminata: a comparative, randomized clinical trial[J]. Photodermatol Photoimmunol Photomed, 2009,25(6):293⁃297. DOI: 10.1111/j.1600⁃0781.2009.00467.x. |
| [75] | Szeimies RM, Schleyer V, Moll I, et al. Adjuvant photodynamic therapy does not prevent recurrence of condylomata acuminata after carbon dioxide laser ablation⁃A phaseⅢ, prospective, randomized, bicentric, double⁃blind study[J]. Dermatol Surg, 2009,35(5):757⁃764. DOI: 10.1111/j.1524⁃4725.2009.01125.x. |
| [76] | Ghiasy S, Fallah⁃Karkan M, Razzaghi MR, et al. Is holmium laser an appropriate modality to treat genital warts?[J]. J Lasers Med Sci, 2019,10(1):70⁃74. DOI: 10.15171/jlms.2019.11. |
| [77] | Del Zingaro M, Cochetti G, Zucchi A, et al. Holmium:YAG laser for the treatment of genital and urethral warts: multicentre prospective evaluation of safety and efficacy[J]. J Lasers Med Sci, 2021,12:e34. DOI: 10.34172/jlms.2021.34. |
| [78] | Stone KM, Becker TM, Hadgu A, et al. Treatment of external genital warts: a randomised clinical trial comparing podophyllin, cryotherapy, and electrodesiccation[J]. Genitourin Med, 1990,66(1):16⁃19. DOI: 10.1136/sti.66.1.16. |
| [79] | Jensen SL. Comparison of podophyllin application with simple surgical excision in clearance and recurrence of perianal condylomata acuminata[J]. Lancet, 1985,2(8465):1146⁃1148. DOI: 10.1016/s0140⁃6736(85)92677⁃7. |
| [80] | Khawaja HT. Podophyllin versus scissor excision in the treatment of perianal condylomata acuminata: a prospective study[J]. Br J Surg, 1989,76(10):1067⁃1068. DOI: 10.1002/bjs.1800 761027. |
| [81] | 宋仕桐, 王鑫怡. 光动力治疗仪联合CO2激光治疗仪对尖锐湿疣的治疗效果研究[J]. 中国医疗器械信息, 2026,32(14):65⁃67. DOI: 10.15971/j.cnki.cmdi.2026.14.019. |
| [82] | Liu M, Hu F, Li G, et al. Recurrence rate of perianal and intra⁃anal genital warts treated with aminolevulinic acid photodynamic therapy: a meta⁃analysis[J]. Front Reprod Health, 2025,7:1746426. DOI: 10.3389/frph.2025.1746426. |
| [83] | Xie X, Zhong H, Tang S, et al. Effect of 5⁃aminolevulinic acid photodynamic therapy combined with carbon dioxide laser on condyloma acuminatum[J]. Indian J Pharm Sci, 2023,85(3):124⁃127. DOI: 10.36468/pharmaceutical⁃sciences.spl.681. |
| [84] | Du J, Lu XN, Li F, et al. Comparison between photodynamic therapy with topical application of 5⁃aminolevulinic acid and CO2 laser therapy in the treatment of cervical condylomata acuminate: a randomized controlled trial[J]. Int J Clin Exp Med, 2015,8(7):11342⁃11346. |
| [85] | Zhao Z, Jama AA, Gao H, et al. Clinical observation of laser combined with 5⁃aminolevulinic acid photodynamic therapy for female vulva condyloma acuminatum[J]. J Obstet Gynaecol Res, 2023,49(8):2010⁃2014. DOI: 10.1111/jog.15679. |
| [86] | Jiang S, Hu X, Peng X, et al. Effect of topical 5⁃aminolevulinic acid⁃mediated photodynamic therapy combined with CO2 laser pretreatment for vaginal condyloma acuminate[J]. Photodiagnosis Photodyn Ther, 2024,46:104008. DOI: 10.1016/j.pdpdt.2024. 104008. |
| [87] | Kechichian E, Helou E, Sarkis J, et al. The place of 5⁃aminolaevulinic acid⁃photodynamic therapy in the treatment landscape of urethral warts: a systematic review[J]. Photodiagnosis Photodyn Ther, 2021,33:102204. DOI: 10.1016/j.pdpdt.2021.102204. |
| [88] | 中华医学会皮肤性病学分会光动力治疗研究协作组, 中国康复医学会皮肤病康复专业委员会及光动力治疗与康复专业委员会, 中国医学装备协会皮肤病与皮肤美容分会光医学治疗装备学组. 氨基酮戊酸光动力疗法治疗尖锐湿疣的临床应用指南(2026版)[J]. 中华皮肤科杂志, 2026,59(7):611⁃618. DOI: 10.35541/cjd.20250702. |
| [89] | 中华医学会皮肤性病学分会, 中国医师协会皮肤科医师分会, 中国康复医学会皮肤性病委员会. 中国尖锐湿疣临床诊疗指南(2021完整版)[J]. 中国皮肤性病学杂志, 2021,35(4):359⁃374. |
| [90] | 中华医学会皮肤性病学分会性病学组. 尖锐湿疣治疗专家共识(2017)[J]. 临床皮肤科杂志, 2018,47(2):125⁃127. DOI: 10.16761/j.cnki.1000⁃4963.2018.02.022. |
| [91] | World Health Organization. Recommendations for the treatment of Trichomonas vaginalis, Mycoplasma genitalium, Candida albicans, bacterial vaginosis and human papillomavirus (anogenital warts)[M/OL]. Geneva:WHO,2024. (2024⁃07⁃16)[2026⁃10⁃20]. https://www.who.int/publications/i/item/978924 0096370. |
| [92] | Temple RW, Larker J, Brus JM. Genital warts: rapid evidence review[J]. Am Fam Physician, 2025,111(2):156⁃162. |
| [93] | Culton DA, Morrell DS, Burkhart CN. The management of condyloma acuminata in the pediatric population[J]. Pediatr Ann, 2009,38(7):368⁃372. DOI: 10.3928/00904481⁃20090622⁃05. |
| [94] | Moresi JM, Herbert CR, Cohen BA. Treatment of anogenital warts in children with topical 0.05% podofilox gel and 5% imiquimod cream[J]. Pediatr Dermatol, 2001,18(5):448⁃450; discussion 452. DOI: 10.1046/j.1525⁃1470.2001.1980a.x. |
| [95] | Grussendorf⁃Conen EI, Jacobs S. Efficacy of imiquimod 5% cream in the treatment of recalcitrant warts in children[J]. Pediatr Dermatol, 2002,19(3):263⁃266. DOI: 10.1046/j.1525⁃1470.2002.00083.x. |
| [96] | Xu M, Lin N, Li J, et al. Photodynamic therapy as an alternative therapeutic option for pediatric condyloma acuminata: a case series[J]. Photodiagnosis Photodyn Ther, 2018,24:179⁃181. DOI: 10.1016/j.pdpdt.2018.09.010. |
| [97] | Mihailov R, Tatu AL, Niculet E, et al. Surgical management of perianal giant condyloma acuminatum of Buschke and Löwenstein: case presentation[J]. Life (Basel), 2023,13(9):1916. DOI: 10.3390/life13091916. |
| [98] | Yildiz A, Leventoglu S, Yildiz A, et al. Radical surgical management of perianal giant condyloma acuminatum of Buschke and Löwenstein: long⁃term results of 11 cases[J]. Ann Coloproctol, 2023,39(3):204⁃209. DOI: 10.3393/ac.2021.00080. 0011. |
| [99] | Grosu⁃Bularda A, Hariga CS, Dumitru CS, et al. Clinicopathological findings and comprehensive review of Buschke⁃Löwenstein tumors based on a case study[J]. J Pers Med, 2024,14(8):887. DOI: 10.3390/jpm14080887. |
| [100] | Davis KG, Barton JS, Orangio G, et al. Buschke⁃Löwenstein tumors: a review and proposed classification system[J]. Sex Transm Dis, 2021,48(12):e263⁃e268. DOI: 10.1097/OLQ. 0000000000001437. |
| [101] | Kim WB, Lee SJ, Bae S, et al. Korean sexually transmitted infection guidelines 2023 revision, guideline update of viral infections: genital herpes and anogenital warts[J]. Investig Clin Urol, 2024,65(1):9⁃15. DOI: 10.4111/icu.20230275. |
| [102] | Wen LM, Estcourt CS, Simpson JM, et al. Risk factors for the acquisition of genital warts: are condoms protective?[J]. Sex Transm Infect, 1999,75(5):312⁃316. DOI: 10.1136/sti.75.5.312. |
| [103] | Giuliano AR, Palefsky JM, Goldstone S, et al. Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males[J]. N Engl J Med, 2011,364(5):401⁃411. DOI: 10. 1056/NEJMoa0909537. |
| [104] | Garland SM, Hernandez⁃Avila M, Wheeler CM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases[J]. N Engl J Med, 2007,356(19):1928⁃1943. DOI: 10.1056/NEJMoa061760. |
| [105] | Goldstone SE, Giuliano AR, Palefsky JM, et al. Efficacy, immunogenicity, and safety of a quadrivalent HPV vaccine in men: results of an open⁃label, long⁃term extension of a randomised, placebo⁃controlled, phase 3 trial[J]. Lancet Infect Dis, 2022,22(3):413⁃425. DOI: 10.1016/S1473⁃3099(21)00327⁃3. |
| [106] | Ferris DG, Samakoses R, Block SL, et al. 4⁃Valent human papillomavirus (4vHPV) vaccine in preadolescents and adolescents after 10 years[J]. Pediatrics, 2017,140(6): 3947. DOI: 10.1542/peds.2016⁃3947. |
| [107] | Maldonado I, Plata M, Gonzalez M, et al. Effectiveness, immunogenicity, and safety of the quadrivalent HPV vaccine in women and men aged 27-45 years[J]. Hum Vaccin Immunother, 2022,18(5):2078626. DOI: 10.1080/21645515. 2022.2078626. |
| [108] | Lukács A, Máté Z, Farkas N, et al. The quadrivalent HPV vaccine is protective against genital warts: a meta⁃analysis[J]. BMC Public Health, 2020,20(1):691. DOI: 10.1186/s12889⁃020⁃08753⁃y. |
| [109] | Dominiak⁃Felden G, Gobbo C, Simondon F. Evaluating the early benefit of quadrivalent HPV vaccine on genital warts in Belgium: a cohort study[J]. PLoS One, 2015,10(7):e0132404. DOI: 10.1371/journal.pone.0132404. |
| [110] | Chow E, Carter A, Vickers T, et al. Effect on genital warts in Australian female and heterosexual male individuals after introduction of the national human papillomavirus gender⁃neutral vaccination programme: an analysis of national sentinel surveillance data from 2004⁃18[J]. Lancet Infect Dis, 2021,21(12):1747⁃1756. DOI: 10.1016/S1473⁃3099(21)00071⁃2. |
| [111] | Rashid H, Dey A, Wang H, et al. Sustained decline in hospitalisations for anogenital warts in Australia: analysis of national hospital morbidity data 2003⁃2020[J]. Trop Med Infect Dis, 2024,9(4):79. DOI: 10.3390/tropicalmed9040079. |
| [112] | American College of Obstetricians and Gynecologists' Committee on Adolescent Health Care, American College of Obstetricians and Gynecologists' Immunization, Infectious Disease, and Public Health Preparedness Expert Work Group. Human papillomavirus vaccination: ACOG Committee Opinion, Number 809[J]. Obstet Gynecol, 2020,136(2):e15⁃e21. DOI: 10.1097/AOG.0000000000004000. |
| [113] | Meites E, Szilagyi PG, Chesson HW, et al. Human papillomavirus vaccination for adults: updated recommendations of the Advisory Committee on Immunization Practices[J]. MMWR Morb Mortal Wkly Rep, 2019,68(32):698⁃702. DOI: 10.15585/mmwr.mm6832a3. |
| [114] | Pruski D, Millert⁃Kalińska S, Łagiedo M, et al. Effect of HPV vaccination on virus disappearance in cervical samples of a cohort of HPV⁃positive Polish patients[J]. J Clin Med, 2023,12(24):7592. DOI: 10.3390/jcm12247592. |
| [115] | Pruski D, Millert⁃Kalińska S, Jach R, et al. Effect of vaccination against HPV in the HPV⁃positive patients not covered by primary prevention on the disappearance of infection[J]. Sci Rep, 2025,15(1):12642. DOI: 10.1038/s41598⁃025⁃92861⁃5. |
| [116] | Protasov AD, Lipatov IS, Kostinov MP, et al. Anogenital warts: a new way of solving the common problem of urology (results of long⁃term follow⁃up)[J]. Urologiia, 2016,2016(5):47⁃51. |
| [117] | Joura EA, Garland SM, Paavonen J, et al. Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial data[J]. BMJ, 2012,344:e1401. DOI: 10.1136/bmj.e1401. |
| [118] | Choi H. Can quadrivalent human papillomavirus prophylactic vaccine be an effective alternative for the therapeutic management of genital warts? An exploratory study[J]. Int Braz J Urol, 2019,45(2):361⁃368. DOI: 10.1590/S1677⁃5538.IBJU.2018.0355. |
| [119] | Hansen BT, Hagerup⁃Jenssen M, Kjaer SK, et al. Association between smoking and genital warts: longitudinal analysis[J]. Sex Transm Infect, 2010,86(4):258⁃262. DOI: 10.1136/sti.2009.038273. |
| [120] | Nyitray AG, Carvalho da Silva RJ, Baggio ML, et al. Six⁃month incidence, persistence, and factors associated with persistence of anal human papillomavirus in men: the HPV in men study[J]. J Infect Dis, 2011,204(11):1711⁃1722. DOI: 10.1093/infdis/jir637. |
| [1] | 中华医学会皮肤性病学分会 中华医学会变态反应学分会 中国麻风防治协会. [开放获取] 中国药疹诊疗指南(2026版)[J]. 中华皮肤科杂志, 2026, 59(9): 811-826. |
| [2] | 中华医学会皮肤性病学分会光动力治疗研究协作组 中国康复医学会皮肤病康复专业委员会及光动力治疗与康复专业委员会 中国医学装备协会皮肤病与皮肤美容分会光医学治疗装备学组. 氨基酮戊酸光动力疗法治疗尖锐湿疣的临床应用指南(2026版)[J]. 中华皮肤科杂志, 2026, 59(7): 611-618. |
| [3] | 中国妇幼保健协会儿童变态反应专业委员会儿童皮肤病学组. 儿童肛门生殖器硬化性苔藓诊疗管理中国专家共识(2026版)[J]. 中华皮肤科杂志, 2026, 59(5): 396-406. |
| [4] | 郭清清 齐家跃 解方 李承新. 成纤维细胞生长因子受体3与人乳头瘤病毒2型E2对角质形成细胞分化的初步研究[J]. 中华皮肤科杂志, 2023, 56(11): 1016-1022. |
| [5] | 许翠 何勇 吴亦琳 吕群 李黎明 蒋明军. 人乳头状瘤病毒16 E6/E7基因稳定表达的永生化角质形成细胞的建立及鉴定[J]. 中华皮肤科杂志, 2022, 55(6): 501-507. |
| [6] | 唐洪波 马庆宇 桑莹冰 毛丽旦 梁俊琴 康晓静. 紫外线和人乳头状瘤病毒16 E6协同诱导、促进裸鼠皮肤鳞状细胞癌的机制研究[J]. 中华皮肤科杂志, 2022, 55(11): 982-989. |
| [7] | 陈荃 唐奕 李华平 陈教全 彭丽倩 杨日东 邓蕙妍 李振洁 朱慧兰. 紫檀芪对人乳头瘤病毒16整合感染宫颈上皮细胞系生长、凋亡和自噬的影响[J]. 中华皮肤科杂志, 2021, 54(10): 861-868. |
| [8] | 尹光文 刘聪 王小云 张华 王梦奇. 氨基酮戊酸-光动力疗法对尖锐湿疣组织中血管内皮生长因子和增殖细胞核抗原表达的影响[J]. 中华皮肤科杂志, 2020, 53(1): 48-50. |
| [9] | 黄丹 鞠梅 常宝珠 陈旭 张小华 朱艳 周亚男 许南 陈崑 顾恒. 51例女童尖锐湿疣临床分析[J]. 中华皮肤科杂志, 2018, 51(5): 363-365. |
| [10] | 中国医师协会皮肤科医师分会美容亚专业… 谢红付. [开放获取] 中国玫瑰痤疮诊疗专家共识(2016)[J]. 中华皮肤科杂志, 2017, 50(3): 156-161. |
| [11] | 朱小霞 周强 程浩 朱红明. 尖锐湿疣患者皮损中朗格汉斯细胞和浆细胞样树突细胞的检测[J]. 中华皮肤科杂志, 2015, 48(5): 343-345. |
| [12] | 张筱雁 王琳. 肛周丘疹性棘层松解性皮病一例[J]. 中华皮肤科杂志, 2015, 48(12): 890-891. |
| [13] | 缪飞 王秀丽 吕婷 石磊 张玲琳 王宏伟. 光动力疗法对表达人乳头瘤病毒16 E7蛋白的HaCaT细胞株增殖和凋亡的影响[J]. 中华皮肤科杂志, 2015, 48(10): 683-686. |
| [14] | 赵建光 禹志成. 液氮冷冻联合卡介菌多糖核酸治疗尖锐湿疣疗效观察[J]. 中华皮肤科杂志, 2012, 45(9): 677-677. |
| [15] | 郑双进 黎兆军 樊翌明. 尖锐湿疣组织内血管内皮生长因子和转化生长因子-α表达[J]. 中华皮肤科杂志, 2011, 44(5): 350-351. |
|